Focused On-demand Library for RCC1 and BTB domain-containing protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8NDN9

UPID:

RCBT1_HUMAN

Alternative names:

Chronic lymphocytic leukemia deletion region gene 7 protein; Regulator of chromosome condensation and BTB domain-containing protein 1

Alternative UPACC:

Q8NDN9; Q8IY29; Q969U9

Background:

RCC1 and BTB domain-containing protein 1, also known as Chronic lymphocytic leukemia deletion region gene 7 protein, plays a crucial role in cell cycle regulation through chromatin remodeling. Its alternative name, Regulator of chromosome condensation and BTB domain-containing protein 1, underscores its significance in genetic stability and cellular function.

Therapeutic significance:

Linked to Retinal dystrophy with or without extraocular anomalies, this protein's dysfunction manifests in progressive retinal dystrophy, chorioretinal macular atrophy, and other systemic anomalies. Understanding its role could lead to novel therapeutic strategies for these conditions.